Dr. Tsai’s research has been focusing on developing novel treatments for CNS disorders. He and his group have successfully identified several new drug targets that will improve the symptoms and quality of life of people with mental illness. The treatment is based upon the N-methyl-D-aspartate (NMDA) receptor mechanism. He had shown that the NMDA therapeutics worked for populations refractory to the available treatments based upon our proof the principle studies at both the bench and bedside. It is not surprising that the novel therapeutics can benefit conditions including schizophrenia, depression, obsessive compulsive disorder, attention deficit hyperactivity disorder, mild cognitive impairment, Parkinson and dementia, for the NMDA receptor mechanism is the main regulatory mechanism of memory and cognition of brain function.
Massachusetts General Hospital
MGH Research Fellows
Interview: Guochuan Emil Tsai, MD MAS – Founder & CEO, SyneuRx, Taiwan